Get notified when SXTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Vie Agreements (new) — The company's control over its main operating entity rests on untested contractual arrangements, which may not hold up in Chinese courts.
- Dilution From Warrants (new) — Warrants for up to 63 million additional shares could nearly triple the share count if exercised, causing severe dilution to existing shareholders.
- Nasdaq Delisting Risk (new) — The company's shares must maintain a minimum average closing price of $1.00 over 30 consecutive business days to remain listed on Nasdaq, and failure to do so could lead to delisting.
China SXT Pharmaceuticals prices $9M offering of 4.5M shares at $2.00, plus warrants for up to 63M more shares
Filed July 24, 2026 · ~1 min read
Key Changes
-
high
Offering of 4.5M Class A ordinary shares at $2.00 per share, with warrants to purchase up to 63M additional shares; net proceeds to company estimated at $8.28M.
The Offering verify on EDGAR → -
medium
Net proceeds of $8.28M will be used for general corporate purposes and working capital, with no specific uses identified.
Use of Proceeds verify on EDGAR → -
high
Existing shareholders face immediate dilution of $0.49 per share; new investors face $1.60 per share dilution at the $2.00 offering price.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade SXTC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify